MRI/MR spectroscopy falls short for prostate cancer

By staff writers

April 23, 2009 -- Combined MRI/MR spectroscopy (MRSI) doesn't provide additional benefit over MRI alone for staging prostate cancer, according to results from a study from the American College of Radiology Imaging Network (ACRIN).

ACRIN study 6659, MR Imaging and MR Spectroscopic Imaging of Prostate Cancer Prior to Radical Prostatectomy, found that the accuracy of combined 1.5-tesla endorectal MRI and magnetic spectroscopic imaging is equal to that of MRI alone. The study was published in the April 2009 issue of Radiology.

From February 2004 to June 2005, 134 participants with biopsy-proved prostate cancer who were scheduled to undergo radical prostatectomy were enrolled from seven sites in the U.S. When the study was completed, ACRIN convened a panel to correlate the MRI images and MRSI data with histopathologic specimen data that served as the reference standard.

Although this combined imaging technique held significant promise, the data analysis did not confirm the trial's primary hypothesis of combined MRI/MRSI performing better than MRI alone, ACRIN said.

Longer hormone therapy may improve outcomes in advanced prostate cancer, April 15, 2009

SBRT for early prostate cancer shows promising interim results, April 9, 2009

No benefit seen with adjuvant radiotherapy after radical prostatectomy, March 25, 2009

IGRT corrects for prostate shift in obese patients during treatment, March 23, 2009

Radiation added to hormone therapy beneficial in locally advanced prostate cancer, September 23, 2008

Copyright © 2009


To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking